We systematically work on establishing Mediprime as a truly integrated care provider that offers the most comprehensive portfolio of products for those who suffer from renal disease. Our objective is to drive better patient care in the treatment of Chronic Kidney Disease, by combining our therapeutic systems portfolio with high-quality pharmaceutical solutions.

Our focused pharmaceuticals portfolio includes:

  • Sevelamer Carbonate
    Indication: Control of hyperphosphataemia in adult patients receiving haemodialysis or peritoneal dialysis.
  • Paricalcitol
    Indication: Prevention and treatment of secondary hyperparathyroidism associated with chronic renal failure.
  • Cinacalcet
    Indication: Treatment of hyperparathyroidism, a consequence of parathyroid tumors and chronic renal failure.
By continuing on this website you accept the use of cookies on your device as described in the Privacy Policy.